• Reference Citation Analysis
  • v
  • v
  • Find an Article
Download
Number Select Citation Analysis of Khalid El Bairi's Published Articles
1 Lengyel CG, Hussain S, Seeber A, Jamil Nidhamalddin S, Trapani D, Habeeb BS, Elfaham E, Mazher SA, Seid F, Khan SZ, El Bairi K, Odhiambo A, Altuna SC, Petrillo A. FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target? Life (Basel) 2022;12:81. [PMID: 35054474 DOI: 10.3390/life12010081] [Cited by in Crossref: 2] [Cited by in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
2 El Bairi K, Al Jarroudi O, Afqir S. Practical Tools and Guidelines for Young Oncologists From Resource-Limited Settings to Publish Excellence and Advance Their Career. JCO Glob Oncol 2021;7:1668-81. [PMID: 34910583 DOI: 10.1200/GO.21.00310] [Cited by in Crossref: 1] [Cited by in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
3 El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno-Oncology Biomarker Working Group. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer 2021;7:150. [PMID: 34853355 DOI: 10.1038/s41523-021-00346-1] [Cited by in Crossref: 24] [Cited by in RCA: 21] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
4 El Bairi K, Al Jarroudi O, Afqir S. Inexpensive Systemic Inflammatory Biomarkers in Ovarian Cancer: An Umbrella Systematic Review of 17 Prognostic Meta-Analyses. Front Oncol 2021;11:694821. [PMID: 34631526 DOI: 10.3389/fonc.2021.694821] [Cited by in Crossref: 2] [Cited by in RCA: 1] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
5 El Bairi K, Al Jarroudi O, Afqir S. Ovarian cancer in Morocco: Time to act is now. Gynecol Oncol Rep 2021;37:100857. [PMID: 34541276 DOI: 10.1016/j.gore.2021.100857] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
6 Al Jarroudi O, El Bairi K, Abda N, Zaimi A, Jaouani L, Chibani H, Afqir S. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer. Biomark Med 2021;15:1289-98. [PMID: 34486882 DOI: 10.2217/bmm-2020-0717] [Cited by in Crossref: 3] [Cited by in RCA: 2] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
7 El Bairi K, Singh S, Le Page C. Revisiting platinum-resistant ovarian cancer: Advances in therapy, molecular biomarkers, and clinical outcomes. Semin Cancer Biol 2021:S1044-579X(21)00226-1. [PMID: 34492299 DOI: 10.1016/j.semcancer.2021.09.002] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
8 Bairi KE, Amrani M. The Power of Biomarkers in Transforming Patients Care in Gynecologic Oncology. Curr Drug Targets 2020;21:944-5. [PMID: 32729410 DOI: 10.2174/138945012110200624104942] [Cited by in Crossref: 1] [Cited by in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
9 Trapani D, Lengyel C, Habeeb B, Altuna S, Petrillo A, El Bairi K, Hussain S, Mazher S, Elfaham E, Curigliano G, Khan S. The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey. J Cancer Policy 2021;28:100285. [PMID: 35559914 DOI: 10.1016/j.jcpo.2021.100285] [Cited by in Crossref: 4] [Cited by in RCA: 1] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
10 Lengyel CG, Hussain S, Trapani D, El Bairi K, Altuna SC, Seeber A, Odhiambo A, Habeeb BS, Seid F. The Emerging Role of Liquid Biopsy in Gastric Cancer. J Clin Med 2021;10:2108. [PMID: 34068319 DOI: 10.3390/jcm10102108] [Cited by in Crossref: 7] [Cited by in RCA: 6] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
11 El Bairi K, Al Jarroudi O, Afqir S. Tracing ovarian cancer research in Morocco: A bibliometric analysis. Gynecol Oncol Rep 2021;37:100777. [PMID: 34150972 DOI: 10.1016/j.gore.2021.100777] [Cited by in Crossref: 1] [Cited by in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
12 El Bairi K, Al Jarroudi O, Afqir S. Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer. Semin Cancer Biol 2021:S1044-579X(21)00081-X. [PMID: 33812984 DOI: 10.1016/j.semcancer.2021.03.031] [Cited by in Crossref: 1] [Cited by in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
13 El Bairi K, Al Jarroudi O, Le Page C, Afqir S. Does the "Devil" originate from the fallopian tubes? Semin Cancer Biol 2021:S1044-579X(21)00068-7. [PMID: 33766647 DOI: 10.1016/j.semcancer.2021.03.018] [Cited by in Crossref: 5] [Cited by in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
14 Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT; International Natural Product Sciences Taskforce. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov 2021;20:200-16. [PMID: 33510482 DOI: 10.1038/s41573-020-00114-z] [Cited by in Crossref: 665] [Cited by in RCA: 526] [Impact Index Per Article: 665.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
15 El Bairi K, Trapani D, Petrillo A, Le Page C, Zbakh H, Daniele B, Belbaraka R, Curigliano G, Afqir S. Repurposing anticancer drugs for the management of COVID-19. Eur J Cancer 2020;141:40-61. [PMID: 33125946 DOI: 10.1016/j.ejca.2020.09.014] [Cited by in Crossref: 37] [Cited by in RCA: 31] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
16 El Bairi K, Afqir S, Amrani M. Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer? Curr Drug Targets 2020;21:1026-33. [PMID: 32334501 DOI: 10.2174/1389450121666200425211732] [Cited by in Crossref: 4] [Cited by in RCA: 3] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
17 El Bairi K, Jabi R, Trapani D, Boutallaka H, Ouled Amar Bencheikh B, Bouziane M, Amrani M, Afqir S, Maleb A. Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut. Expert Rev Clin Pharmacol 2020;13:403-21. [PMID: 32308061 DOI: 10.1080/17512433.2020.1758063] [Cited by in Crossref: 3] [Cited by in RCA: 2] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
18 Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R; International Immuno-Oncology Biomarker Working Group. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer 2020;6:17. [PMID: 32411819 DOI: 10.1038/s41523-020-0156-0] [Cited by in Crossref: 58] [Cited by in RCA: 48] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
19 Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM; International Immuno-Oncology Biomarker Working Group. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. NPJ Breast Cancer 2020;6:15. [PMID: 32436923 DOI: 10.1038/s41523-020-0155-1] [Cited by in Crossref: 9] [Cited by in RCA: 7] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
20 Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Laenkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta-Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Sotiriou C, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon-Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M; International Immuno-Oncology Biomarker Working Group. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol 2020;250:667-84. [PMID: 32129476 DOI: 10.1002/path.5406] [Cited by in Crossref: 91] [Cited by in RCA: 81] [Impact Index Per Article: 45.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
21 El Bairi K, Atanasov AG, Amrani M, Afqir S. The arrival of predictive biomarkers for monitoring therapy response to natural compounds in cancer drug discovery. Biomed Pharmacother 2019;109:2492-8. [PMID: 30551510 DOI: 10.1016/j.biopha.2018.11.097] [Cited by in Crossref: 15] [Cited by in RCA: 11] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
22 El Bairi K, Amrani M, Afqir S. Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers. Cancer Med 2018;7:2221-46. [PMID: 29732738 DOI: 10.1002/cam4.1467] [Cited by in Crossref: 5] [Cited by in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
23 El Bairi K, Tariq K, Himri I, Jaafari A, Smaili W, Kandhro AH, Gouri A, Ghazi B. Decoding colorectal cancer epigenomics. Cancer Genet 2018;220:49-76. [PMID: 29310839 DOI: 10.1016/j.cancergen.2017.11.001] [Cited by in Crossref: 33] [Cited by in RCA: 27] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
24 El Bairi K, Amrani M, Afqir S. The Human Cancer Pathology Atlas: An open-access source for more than 900,000 Kaplan-Meier plots and 5 million cancer tissue images. Biomed Pharmacother 2017;96:1438-9. [PMID: 29055506 DOI: 10.1016/j.biopha.2017.10.063] [Cited by in Crossref: 2] [Cited by in RCA: 1] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
25 El Bairi K, Ouzir M, Agnieszka N, Khalki L. Anticancer potential of Trigonella foenum graecum: Cellular and molecular targets. Biomed Pharmacother 2017;90:479-91. [PMID: 28391170 DOI: 10.1016/j.biopha.2017.03.071] [Cited by in Crossref: 30] [Cited by in RCA: 25] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
26 El Bairi K, Amrani M, Kandhro AH, Afqir S. Prediction of therapy response in ovarian cancer: Where are we now? Crit Rev Clin Lab Sci 2017;54:233-66. [PMID: 28443762 DOI: 10.1080/10408363.2017.1313190] [Cited by in Crossref: 23] [Cited by in RCA: 18] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
27 El Bairi K, Kandhro AH, Gouri A, Mahfoud W, Louanjli N, Saadani B, Afqir S, Amrani M. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer. Cell Oncol (Dordr) 2017;40:105-18. [PMID: 27981507 DOI: 10.1007/s13402-016-0309-1] [Cited by in Crossref: 36] [Cited by in RCA: 31] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
28 Khalid EB, Ayman EE, Rahman H, Abdelkarim G, Najda A. Natural products against cancer angiogenesis. Tumour Biol 2016;37:14513-36. [PMID: 27651162 DOI: 10.1007/s13277-016-5364-8] [Cited by in Crossref: 61] [Cited by in RCA: 56] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
29 Gouri A, Dekaken A, El Bairi K, Aissaoui A, Laabed N, Chefrour M, Ciccolini J, Milano G, Benharkat S. Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine. Biomark Insights 2016;11:105-11. [PMID: 27578963 DOI: 10.4137/BMI.S33372] [Cited by in Crossref: 16] [Cited by in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
30 Ouzir M, El Bairi K, Amzazi S. Toxicological properties of fenugreek (Trigonella foenum graecum). Food Chem Toxicol 2016;96:145-54. [PMID: 27498339 DOI: 10.1016/j.fct.2016.08.003] [Cited by in Crossref: 65] [Cited by in RCA: 50] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)]
31 Beghlal D, El Bairi K, Marmouzi I, Haddar L, Mohamed B. Phytochemical, organoleptic and ferric reducing properties of essential oil and ethanolic extract from Pistacia lentiscus (L.). Asian Pac J Trop Dis 2016;6:305-10. [DOI: 10.1016/s2222-1808(15)61035-0] [Cited by in Crossref: 13] [Cited by in RCA: 8] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
PrevPage 1 of 1 1Next
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA